The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines
Yonghui Liu,1 Zhaoyu Wang,1 Fan Yu,2 Mingjing Li,1 Haomiao Zhu,1 Kun Wang,1 Meng Meng,1 Wei Zhao1 1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin 300353, People’s Republic of China; 2College of Life Sciences, Nanka...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1cbb017c82084298aa5766b65ecbd510 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1cbb017c82084298aa5766b65ecbd510 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1cbb017c82084298aa5766b65ecbd5102021-12-02T16:05:26ZThe Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines1178-2013https://doaj.org/article/1cbb017c82084298aa5766b65ecbd5102021-01-01T00:00:00Zhttps://www.dovepress.com/the-adjuvant-of-alpha-galactosylceramide-presented-by-gold-nanoparticl-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yonghui Liu,1 Zhaoyu Wang,1 Fan Yu,2 Mingjing Li,1 Haomiao Zhu,1 Kun Wang,1 Meng Meng,1 Wei Zhao1 1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin 300353, People’s Republic of China; 2College of Life Sciences, Nankai University, Tianjin 300071, People’s Republic of ChinaCorrespondence: Meng Meng; Wei ZhaoState Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, No. 38 Tongyan Road, Haihe Education Park, Tianjin 300353, People’s Republic of ChinaTel/Fax +86 22-23507760Email mengmeng@nankai.edu.cn; wzhao@nankai.edu.cnBackground: Therapeutic tumor vaccines are one of the most promising strategies and have attracted great attention in cancer treatment. However, most of them have shown unsatisfactory immunogenicity, there are still few available vaccines for clinical use. Therefore, there is an urgent demand to develop novel strategies to improve the immune efficacy of antitumor vaccines.Purpose: This study aimed to develop novel adjuvants and carriers to enhance the immune effect of MUC1 glycopeptide antigen-based antitumor vaccines.Methods: An antitumor vaccine was developed, in which MUC1 glycopeptide was used as tumor-associated antigen, α-GalCer served as an immune adjuvant and AuNPs was a multivalent carrier.Results: Immunological evaluation results indicated that the constructed vaccines enabled a significant antibody response. FACS analysis and immunofluorescence assay showed that the induced antisera exhibited a specific binding with MUC1 positive MCF-7 cells. Moreover, the induced antibody can mediate CDC to kill MCF-7 cells. Besides stimulating B cells to produce MUC1-specific antibodies, the prepared vaccines also induced MUC1-specific CTLs in vitro. Furthermore, the vaccines significantly delayed tumor development in tumor-bearing mice model.Conclusion: These results showed that the construction of vaccines by presenting α-GalCer adjuvant and an antigen on gold nanoparticles offers a potential strategy to improve the antitumor response in cancer immunotherapy.Keywords: MUC1 glycopeptide, α-galactosylceramide, gold nanoparticle, antitumor vaccineLiu YWang ZYu FLi MZhu HWang KMeng MZhao WDove Medical Pressarticlemuc1 glycopeptideα-galactosylceramidegold nanoparticleantitumor vaccineMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 403-420 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
muc1 glycopeptide α-galactosylceramide gold nanoparticle antitumor vaccine Medicine (General) R5-920 |
| spellingShingle |
muc1 glycopeptide α-galactosylceramide gold nanoparticle antitumor vaccine Medicine (General) R5-920 Liu Y Wang Z Yu F Li M Zhu H Wang K Meng M Zhao W The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines |
| description |
Yonghui Liu,1 Zhaoyu Wang,1 Fan Yu,2 Mingjing Li,1 Haomiao Zhu,1 Kun Wang,1 Meng Meng,1 Wei Zhao1 1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin 300353, People’s Republic of China; 2College of Life Sciences, Nankai University, Tianjin 300071, People’s Republic of ChinaCorrespondence: Meng Meng; Wei ZhaoState Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, No. 38 Tongyan Road, Haihe Education Park, Tianjin 300353, People’s Republic of ChinaTel/Fax +86 22-23507760Email mengmeng@nankai.edu.cn; wzhao@nankai.edu.cnBackground: Therapeutic tumor vaccines are one of the most promising strategies and have attracted great attention in cancer treatment. However, most of them have shown unsatisfactory immunogenicity, there are still few available vaccines for clinical use. Therefore, there is an urgent demand to develop novel strategies to improve the immune efficacy of antitumor vaccines.Purpose: This study aimed to develop novel adjuvants and carriers to enhance the immune effect of MUC1 glycopeptide antigen-based antitumor vaccines.Methods: An antitumor vaccine was developed, in which MUC1 glycopeptide was used as tumor-associated antigen, α-GalCer served as an immune adjuvant and AuNPs was a multivalent carrier.Results: Immunological evaluation results indicated that the constructed vaccines enabled a significant antibody response. FACS analysis and immunofluorescence assay showed that the induced antisera exhibited a specific binding with MUC1 positive MCF-7 cells. Moreover, the induced antibody can mediate CDC to kill MCF-7 cells. Besides stimulating B cells to produce MUC1-specific antibodies, the prepared vaccines also induced MUC1-specific CTLs in vitro. Furthermore, the vaccines significantly delayed tumor development in tumor-bearing mice model.Conclusion: These results showed that the construction of vaccines by presenting α-GalCer adjuvant and an antigen on gold nanoparticles offers a potential strategy to improve the antitumor response in cancer immunotherapy.Keywords: MUC1 glycopeptide, α-galactosylceramide, gold nanoparticle, antitumor vaccine |
| format |
article |
| author |
Liu Y Wang Z Yu F Li M Zhu H Wang K Meng M Zhao W |
| author_facet |
Liu Y Wang Z Yu F Li M Zhu H Wang K Meng M Zhao W |
| author_sort |
Liu Y |
| title |
The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines |
| title_short |
The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines |
| title_full |
The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines |
| title_fullStr |
The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines |
| title_full_unstemmed |
The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines |
| title_sort |
adjuvant of α-galactosylceramide presented by gold nanoparticles enhances antitumor immune responses of muc1 antigen-based tumor vaccines |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/1cbb017c82084298aa5766b65ecbd510 |
| work_keys_str_mv |
AT liuy theadjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT wangz theadjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT yuf theadjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT lim theadjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT zhuh theadjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT wangk theadjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT mengm theadjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT zhaow theadjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT liuy adjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT wangz adjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT yuf adjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT lim adjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT zhuh adjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT wangk adjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT mengm adjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines AT zhaow adjuvantofalphagalactosylceramidepresentedbygoldnanoparticlesenhancesantitumorimmuneresponsesofmuc1antigenbasedtumorvaccines |
| _version_ |
1718385133193527296 |